Bolt Biotherapeutics Net Worth
Bolt Biotherapeutics Net Worth Breakdown | BOLT |
Bolt Biotherapeutics Net Worth Analysis
Bolt Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Bolt Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Bolt Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Bolt Biotherapeutics' net worth analysis. One common approach is to calculate Bolt Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Bolt Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Bolt Biotherapeutics' net worth. This approach calculates the present value of Bolt Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Bolt Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Bolt Biotherapeutics' net worth. This involves comparing Bolt Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Bolt Biotherapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Bolt Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bolt Biotherapeutics' net worth research are outlined below:
| Bolt Biotherapeutics generated a negative expected return over the last 90 days | |
| Bolt Biotherapeutics has some characteristics of a very speculative penny stock | |
| Bolt Biotherapeutics has high historical volatility and very poor performance | |
| Bolt Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 7.88 M. Net Loss for the year was (69.2 M) with loss before overhead, payroll, taxes, and interest of (52.29 M). | |
| Bolt Biotherapeutics currently holds about 176.34 M in cash with (69.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Disposition of 12000 shares by Sarah Nemec of Bolt Biotherapeutics at 4.51 subject to Rule 16b-3 |
Bolt Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bolt Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bolt Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Bolt Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bolt Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bolt Biotherapeutics backward and forwards among themselves. Bolt Biotherapeutics' institutional investor refers to the entity that pools money to purchase Bolt Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Adar1 Capital Management Llc | 2024-12-31 | 245 K | Fmr Inc | 2024-12-31 | 129.3 K | Citadel Advisors Llc | 2024-12-31 | 79 K | Engineers Gate Manager Lp | 2024-12-31 | 72.4 K | Ubs Group Ag | 2024-12-31 | 66.1 K | Bridgeway Capital Management, Llc | 2024-12-31 | 60.2 K | Prudential Investment Management Inc | 2024-09-30 | 59.2 K | Goldman Sachs Group Inc | 2024-12-31 | 50 K | Velan Capital Investment Management Lp | 2024-12-31 | 50 K | Tang Capital Management Llc | 2024-12-31 | 3.8 M | Vivo Capital, Llc | 2024-12-31 | 3.5 M |
Follow Bolt Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.84 M.Market Cap |
|
Project Bolt Biotherapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.39) | (0.41) | |
| Return On Capital Employed | (0.49) | (0.52) | |
| Return On Assets | (0.39) | (0.41) | |
| Return On Equity | (0.71) | (0.67) |
When accessing Bolt Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Bolt Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bolt Biotherapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Bolt Biotherapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bolt Biotherapeutics. Check Bolt Biotherapeutics' Beneish M Score to see the likelihood of Bolt Biotherapeutics' management manipulating its earnings.
Evaluate Bolt Biotherapeutics' management efficiency
Bolt Biotherapeutics has return on total asset (ROA) of (0.3176) % which means that it has lost $0.3176 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6499) %, meaning that it created substantial loss on money invested by shareholders. Bolt Biotherapeutics' management efficiency ratios could be used to measure how well Bolt Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.41 in 2025. Return On Capital Employed is likely to drop to -0.52 in 2025. Non Current Liabilities Total is likely to gain to about 46.8 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 16.1 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.68 | 2.82 | |
| Tangible Book Value Per Share | 2.68 | 2.82 | |
| Enterprise Value Over EBITDA | (0.63) | (0.66) | |
| Price Book Value Ratio | 0.34 | 0.35 | |
| Enterprise Value Multiple | (0.63) | (0.66) | |
| Price Fair Value | 0.34 | 0.35 | |
| Enterprise Value | 59.5 M | 56.5 M |
The decision-making processes within Bolt Biotherapeutics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Enterprise Value Revenue 270.646 | Revenue | Quarterly Revenue Growth (0.55) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bolt Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bolt Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bolt Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bolt Biotherapeutics time-series forecasting models is one of many Bolt Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bolt Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Bolt Biotherapeutics Earnings per Share Projection vs Actual
Bolt Biotherapeutics Corporate Management
| Randall Schatzman | CEO Director | Profile | |
| Edith MD | Chief Officer | Profile | |
| Michael Alonso | Senior Research | Profile | |
| MBA CFA | Chief Officer | Profile | |
| Ming Yin | VP Biometrics | Profile | |
| Bruce MD | Sr Medicine | Profile |
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.